One drug and a hard FDA date
- Mineralys has no product revenue today, so the story depends on lorundrostat reaching the market.
- The FDA accepted the hypertension NDA and set a PDUFA target action date of December 22, 2026.
- The company repurchased future royalty obligations and secured massive funding to back a launch.
- Positive hypertension data lowered clinical risk, but approval is still not guaranteed.
- The CKD study met its endpoints, giving lorundrostat a possible second path if regulators agree.
A hard FDA clock and major financing
Mineralys is a regulatory story with a clear date. The company submitted its NDA for lorundrostat in hypertension in December 2025. The FDA accepted it and set a PDUFA target action date of December 22, 2026.
The bull case is simple. Lorundrostat has already shown positive data in uncontrolled and resistant hypertension, as well as chronic kidney disease. The company recently raised substantial capital and bought out its royalty obligations, meaning it captures more of the economics if the drug is successful.
The bear case is also clear. Mineralys still owns one main drug and has not launched a product before. The recent $500 million debt facility introduces financial leverage and operational covenants, with core intellectual property pledged as collateral. FDA acceptance of the NDA is not the same as approval.
The next big watch item is the FDA decision. Before then, investors should look for launch planning, payer strategy, and any update on whether CKD can move toward a label expansion or needs a larger trial.
Cash now, launch later
Mineralys does not make money from drug sales today. It spends cash to run studies, prepare filings, and build for a possible launch. Its value comes from the chance that lorundrostat becomes an approved medicine.
Lorundrostat was in-licensed from Mitsubishi Tanabe. Mineralys recently paid $200 million upfront to repurchase future royalty obligations, though it may still owe up to $100 million if certain commercial milestones are met.
The company funded operations through its IPO and later equity financings, including a recent $150 million equity offering. It also secured a $500 million term loan facility. This capital provides strong backing heading into a possible commercial launch, but the debt adds risk since core intellectual property is pledged as collateral.
Commercial success will depend on more than FDA approval. Doctors must prescribe the drug, insurers must cover it, and pricing must make sense in a crowded high blood pressure market.
Lorundrostat, by use case
Lorundrostat for uncontrolled hypertension
This is the lead use case and the center of the NDA. The FDA target action date is December 22, 2026.
Lorundrostat for resistant hypertension
This is part of the same high blood pressure filing path. It targets patients whose blood pressure stays high even with other medicines.
Lorundrostat for chronic kidney disease
The Phase 2 Explore-CKD trial met its endpoints, including blood pressure and albuminuria. The open question is whether regulators need a dedicated Phase 3 trial.
Lorundrostat for obstructive sleep apnea
The Phase 2 Explore-OSA trial missed its primary endpoint. This makes OSA a weak near-term value driver, even though blood pressure changes and safety were favorable.
No sales mix yet
Mineralys reported one operating segment and no commercial product revenue in its 2026 updates. The split below is a practical view of the business today: all current effort is development, while commercial products are not yet active.
What can break
FDA rejects or delays lorundrostat
High impact · Medium oddsThe NDA has been accepted, but the drug is not approved yet. The FDA could ask for more safety data, more analysis, labeling limits, or a new study. Since lorundrostat is the main asset, a negative decision would hit the whole company.
One-drug concentration
High impact · High oddsMineralys is built around lorundrostat. If the drug fails in hypertension or gets a narrow label, there is no approved second product to offset the damage. The OSA miss already showed the risk of leaning on one molecule for many uses.
Debt collateral risk
High impact · Low oddsThe company recently entered a $500 million term loan and pledged substantially all its assets, including intellectual property, as collateral. If Mineralys defaults on this loan, lenders could foreclose on the core assets that drive the business.
Launch execution costs
Medium impact · Medium oddsA commercial launch needs sales staff, medical education, payer work, and inventory. While the company is well funded through the PDUFA date with a recent equity raise and debt facility, a broader launch may still require careful cash management.
Pricing and coverage fall short
High impact · Medium oddsHigh blood pressure is a large market, but many older medicines are cheap. Lorundrostat must win a clear place in treatment for insurers and doctors. Approval alone may not equal strong sales.
In one breath
What does Mineralys Therapeutics do?
Mineralys is developing lorundrostat, an oral drug that blocks aldosterone production. Aldosterone is a hormone that can raise blood pressure and affect heart and kidney health.
When is the key FDA date for MLYS?
The FDA set a PDUFA target action date of December 22, 2026 for lorundrostat in hypertension. That is the main near-term catalyst for the stock.
Does Mineralys have revenue?
No. Mineralys is still clinical stage and has not commercialized a product, so it has no product revenue today.
Why did the OSA trial matter?
OSA, or obstructive sleep apnea, was a possible expansion area for lorundrostat. The Phase 2 trial missed its primary endpoint, so it is no longer a near-term driver of the investment case.
